ArticleFrontiers in neurology2025
Association between glymphatic dysfunction and cryptogenic stroke risk in patients with patent foramen ovale: a retrospective cross-sectional study.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patent foramen ovale (PFO) is strongly associated with cryptogenic stroke (CS), but the underlying mechanisms remain incompletely understood. The glymphatic system plays a crucial role in central nervous system homeostasis, and its dysfunction has been implicated in various neurological disorders. This study aimed to evaluate the association between glymphatic dysfunction, assessed by the ALPS (Analysis Along the Perivascular Space) index, and the risk of cryptogenic stroke in patients with PFO. Methods: This retrospective, single-center cross-sectional study enrolled 208 PFO patients, including 52 with cryptogenic stroke and 156 without a history of stroke. All participants underwent brain MRI with diffusion tensor imaging (DTI) to calculate the ALPS index. Clinical data, laboratory tests, and echocardiographic parameters were collected. Multivariate logistic regression was used to identify independent predictors of cryptogenic stroke, and receiver operating characteristic (ROC) curve analysis was performed to assess the diagnostic performance of the ALPS index. Results: Patients with cryptogenic stroke exhibited significantly lower ALPS index values compared to controls (1.31 ± 0.18 vs. 1.52 ± 0.21, Conclusion: In PFO patients, impaired glymphatic function, as indicated by a lower ALPS index, was independently associated with an increased risk of cryptogenic stroke. The ALPS index may serve as a promising non-invasive imaging biomarker for stroke risk stratification in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.